MET and cancer: A study by Baccelli et al. suggested a subpopulation of CTCs displaying CD44 cancer stem cell and bone homing marker, CD47, which inhibits phagocytosis and MET (a hepatocyte growth factor receptor); these have been postulated to reflect the promotion of metastatic and invasive activity (27).